Neuland Laboratories Ltd.
NEULANDLABHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
14 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 14 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20220531 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220808 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221116 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230217 | 2022-12-31 | yes | |
| TRANSCRIPT | 20240213 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240517 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240806 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241112 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250214 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250804 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251112 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260213 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260516 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260810 | 2026-06-30 | yes |
NEULANDLAB
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 21,905.00 |
| 52-week range | 11555.0 – 23995.0 |
| Return 1M | -4.55% |
| Return 3M | 21.96% |
| Return 1Y | 45.81% |
| Return 3Y | 474.74% |
| Return 5Y | 1324.81% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 642.00 |
| Other income | 8.00 |
| Total income | 650.00 |
| Cost of materials consumed | 229.00 |
| Purchases of stock-in-trade | 0.00 |
| Changes in inventories | -8.00 |
| Employee benefit expense | 106.00 |
| Finance costs | 7.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.33 | -0.00 |
| institutions foreign | 0.21 | 0.01 |
| institutions domestic | 0.17 | 0.01 |
| mutual funds | 0.13 | 0.01 |
| public | 0.67 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 14 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 294.00 | 269.00 | 407.00 | 363.00 | 418.00 | 393.00 | 385.00 | 440.00 | 311.00 | 398.00 | 328.00 | 293.00 | 514.00 | 440.00 | 776.00 | 642.00 |
| Other income | 0.00 | 1.00 | 8.00 | 2.00 | 3.00 | 2.00 | 5.00 | 5.00 | 4.00 | 4.00 | 7.00 | 8.00 | 2.00 | 8.00 | 12.00 | 8.00 |
| Total income | 294.00 | 270.00 | 415.00 | 365.00 | 421.00 | 395.00 | 390.00 | 444.00 | 315.00 | 402.00 | 336.00 | 301.00 | 516.00 | 448.00 | 789.00 | 650.00 |
| Cost of materials consumed | 122.00 | 132.00 | 138.00 | 165.00 | 139.00 | 153.00 | 175.00 | 155.00 | 133.00 | 145.00 | 141.00 | 161.00 | 228.00 | 200.00 | 231.00 | 229.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | -11.00 | -26.00 | 35.00 | -19.00 | 13.00 | -11.00 | -37.00 | 22.00 | -16.00 | 21.00 | -14.00 | -48.00 | -44.00 | -11.00 | 39.00 | -8.00 |
| Employee benefit expense | 52.00 | 52.00 | 50.00 | 60.00 | 69.00 | 66.00 | 62.00 | 73.00 | 63.00 | 69.00 | 66.00 | 73.00 | 80.00 | 89.00 | 98.00 | 106.00 |
| Finance costs | 3.00 | 3.00 | 4.00 | 2.00 | 4.00 | 4.00 | 4.00 | 3.00 | 1.00 | 2.00 | 2.00 | 5.00 | 5.00 | 7.00 | 7.00 | 7.00 |
| Depreciation and amortisation | 13.00 | 13.00 | 13.00 | 14.00 | 15.00 | 15.00 | 16.00 | 16.00 | 16.00 | 16.00 | 17.00 | 20.00 | 23.00 | 24.00 | 25.00 | 27.00 |
| Other expenses | 61.00 | 58.00 | 64.00 | 61.00 | 59.00 | 64.00 | 78.00 | 66.00 | 68.00 | 76.00 | 84.00 | 71.00 | 95.00 | 85.00 | 101.00 | 91.00 |
| Total expenses | 241.00 | 231.00 | 305.00 | 282.00 | 299.00 | 290.00 | 298.00 | 335.00 | 266.00 | 330.00 | 297.00 | 283.00 | 387.00 | 393.00 | 501.00 | 452.00 |
| Profit before exceptional items and tax | 53.00 | 39.00 | 110.00 | 83.00 | 122.00 | 104.00 | 92.00 | 109.00 | 49.00 | 72.00 | 39.00 | 18.00 | 129.00 | 54.00 | 287.00 | 198.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.00 | 0.00 | 56.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 53.00 | 39.00 | 110.00 | 83.00 | 122.00 | 104.00 | 92.00 | 130.00 | 49.00 | 128.00 | 39.00 | 18.00 | 129.00 | 54.00 | 287.00 | 198.00 |
| Current tax | 14.00 | 7.00 | 25.00 | 21.00 | 31.00 | 25.00 | 22.00 | 31.00 | 12.00 | 25.00 | 6.00 | 4.00 | 33.00 | 15.00 | 77.00 | 51.00 |
| Deferred tax | 0.00 | 2.00 | 0.00 | 0.00 | 1.00 | -2.00 | 3.00 | 1.00 | 4.00 | 1.00 | 5.00 | -1.00 | 0.00 | -1.00 | -2.00 | -1.00 |
| Tax expense | 15.00 | 8.00 | 26.00 | 21.00 | 32.00 | 23.00 | 25.00 | 32.00 | 17.00 | 26.00 | 11.00 | 4.00 | 33.00 | 14.00 | 75.00 | 50.00 |
| Profit for the period | 38.00 | 31.00 | 85.00 | 62.00 | 89.00 | 81.00 | 68.00 | 98.00 | 33.00 | 102.00 | 28.00 | 14.00 | 97.00 | 41.00 | 213.00 | 148.00 |
| Profit attributable to owners | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.00 | 0.00 | 41.00 | 213.00 | 148.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other comprehensive income | -0.00 | -2.00 | -2.00 | -0.00 | 0.00 | 0.00 | 1.00 | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 | -0.00 | -0.00 | 1.00 | -0.00 |
| Total comprehensive income | 38.00 | 29.00 | 82.00 | 62.00 | 90.00 | 81.00 | 68.00 | 98.00 | 33.00 | 102.00 | 28.00 | 14.00 | 97.00 | 40.00 | 214.00 | 148.00 |
| Earnings per share, basic | 29.97 | 23.81 | 65.90 | 48.23 | 69.56 | 63.44 | 52.66 | 76.28 | 25.60 | 79.18 | 21.67 | 10.83 | 75.49 | 31.62 | 165.76 | 115.10 |
| Earnings per share, diluted | 29.97 | 23.81 | 65.90 | 48.23 | 69.56 | 63.44 | 52.66 | 76.28 | 25.60 | 79.18 | 21.67 | 10.83 | 75.49 | 31.62 | 165.76 | 115.10 |
Annual results, as filed
| Line | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|
| Revenue from operations | 763.00 | 937.00 | 951.00 | 1,191.00 | 1,559.00 | 1,477.00 | 2,023.00 |
| Other income | 4.00 | 16.00 | 2.00 | 10.00 | 13.00 | 21.00 | 30.00 |
| Total income | 767.00 | 953.00 | 953.00 | 1,201.00 | 1,571.00 | 1,497.00 | 2,053.00 |
| Cost of materials consumed | 391.00 | 440.00 | 438.00 | 488.00 | 632.00 | 575.00 | 820.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | -11.00 | -1.00 | -15.00 | -10.00 | -55.00 | 13.00 | -64.00 |
| Employee benefit expense | 124.00 | 150.00 | 182.00 | 202.00 | 257.00 | 272.00 | 341.00 |
| Finance costs | 22.00 | 18.00 | 13.00 | 13.00 | 14.00 | 8.00 | 24.00 |
| Depreciation and amortisation | 31.00 | 40.00 | 49.00 | 53.00 | 60.00 | 66.00 | 92.00 |
| Other expenses | 157.00 | 202.00 | 204.00 | 239.00 | 262.00 | 294.00 | 352.00 |
| Total expenses | 714.00 | 848.00 | 871.00 | 985.00 | 1,170.00 | 1,227.00 | 1,564.00 |
| Profit before exceptional items and tax | 53.00 | 105.00 | 82.00 | 216.00 | 401.00 | 270.00 | 489.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.00 | 0.00 |
| Profit before tax | 53.00 | 105.00 | 82.00 | 216.00 | 401.00 | 346.00 | 489.00 |
| Current tax | 0.00 | 13.00 | 20.00 | 50.00 | 100.00 | 74.00 | 129.00 |
| Deferred tax | 37.00 | 12.00 | -2.00 | 2.00 | 2.00 | 12.00 | -4.00 |
| Tax expense | 37.00 | 25.00 | 18.00 | 52.00 | 101.00 | 86.00 | 125.00 |
| Profit for the period | 16.00 | 81.00 | 64.00 | 164.00 | 300.00 | 260.00 | 364.00 |
| Profit attributable to owners | — | — | — | — | 0.00 | 0.00 | 364.00 |
| Profit attributable to non-controlling interests | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Other comprehensive income | -0.00 | -2.00 | -6.00 | -4.00 | 1.00 | -0.00 | 1.00 |
| Total comprehensive income | 16.00 | 79.00 | 58.00 | 160.00 | 301.00 | 260.00 | 365.00 |
| Earnings per share, basic | 12.63 | 62.85 | 49.74 | 127.45 | 233.89 | 202.74 | 283.71 |
| Earnings per share, diluted | 12.63 | 62.85 | 49.74 | 127.45 | 233.89 | 202.74 | 283.71 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 1,424.00 | 1,580.00 | 1,665.00 | 1,833.00 | 1,944.00 | 2,180.00 | 2,534.00 | 2,930.00 |
| Non-current assets | 805.00 | 819.00 | 831.00 | 911.00 | 977.00 | 1,040.00 | 1,268.00 | 1,447.00 |
| Current assets | 620.00 | 761.00 | 834.00 | 921.00 | 953.00 | 1,139.00 | 1,266.00 | 1,483.00 |
| Property, plant and equipment | 462.00 | 457.00 | 500.00 | 523.00 | 531.00 | 674.00 | 788.00 | 892.00 |
| Capital work-in-progress | 29.00 | 41.00 | 12.00 | 46.00 | 139.00 | 45.00 | 140.00 | 209.00 |
| Goodwill | 279.00 | 279.00 | 279.00 | 279.00 | 279.00 | 279.00 | 279.00 | 279.00 |
| Other intangible assets | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 6.00 | 5.00 |
| Inventories | 288.00 | 279.00 | 296.00 | 350.00 | 386.00 | 386.00 | 548.00 | 510.00 |
| Trade receivables | 258.00 | 362.00 | 325.00 | 374.00 | 306.00 | 316.00 | 441.00 | 541.00 |
| Cash and cash equivalents | 6.00 | 45.00 | 125.00 | 88.00 | 72.00 | 132.00 | 41.00 | 77.00 |
| Total equity and liabilities | 1,424.00 | 1,580.00 | 1,665.00 | 1,833.00 | 1,944.00 | 2,180.00 | 2,534.00 | 2,930.00 |
| Equity | 883.00 | 994.00 | 1,133.00 | 1,283.00 | 1,395.00 | 1,525.00 | 1,620.00 | 1,874.00 |
| Equity share capital | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 |
| Other equity | 870.00 | 981.00 | 1,120.00 | 1,270.00 | 1,382.00 | 1,512.00 | 1,607.00 | 1,862.00 |
| Total liabilities | 542.00 | 586.00 | 532.00 | 550.00 | 549.00 | 655.00 | 914.00 | 1,056.00 |
| Non-current liabilities | 164.00 | 147.00 | 129.00 | 122.00 | 135.00 | 189.00 | 270.00 | 345.00 |
| Current liabilities | 378.00 | 439.00 | 403.00 | 428.00 | 409.00 | 466.00 | 644.00 | 710.00 |
| Borrowings, non-current | 90.00 | 74.00 | 59.00 | 45.00 | 51.00 | 91.00 | 89.00 | 161.00 |
| Borrowings, current | 110.00 | 47.00 | 37.00 | 38.00 | 43.00 | 45.00 | 71.00 | 36.00 |
| Trade payables | 123.00 | 171.00 | 179.00 | 192.00 | 223.00 | 252.00 | 290.00 | 269.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 83.00 | 237.00 | 165.00 | 261.00 | 149.00 | 317.00 | -37.00 | 347.00 |
| Net cash from investing activities | -32.00 | -61.00 | -38.00 | -150.00 | -154.00 | -298.00 | -52.00 | -424.00 |
| Net cash from financing activities | -50.00 | -136.00 | -47.00 | -69.00 | -10.00 | 25.00 | -2.00 | 21.00 |
| Purchase of property, plant and equipment | 34.00 | 66.00 | 42.00 | 141.00 | 103.00 | 206.00 | 165.00 | 390.00 |
| Net increase in cash | 1.00 | 40.00 | 80.00 | 42.00 | -15.00 | 44.00 | -91.00 | -55.00 |
| con:CFO.BEFORE_TAX | 95.00 | 281.00 | 224.00 | 373.00 | 194.00 | 392.00 | 3.00 | 450.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 12.00 | 44.00 | 59.00 | 112.00 | 44.00 | 75.00 | 40.00 | 104.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 1.00 | 0.00 | 1.00 | 1.00 | 1.00 | 0.00 | 1.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 36.14 | 36.03 | 35.97 | 32.80 | 32.74 | 32.72 | 32.64 | 32.68 | 32.68 | 32.68 | 0.33 | 0.33 | 0.33 | 0.33 |
| Domestic institutions | 7.10 | 6.76 | 6.99 | 6.03 | 6.54 | 6.39 | 6.38 | 9.08 | 10.97 | 11.57 | 0.14 | 0.15 | 0.16 | 0.17 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 7.66 | 0.10 | 0.10 | 0.11 | 0.13 |
| Insurance companies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.40 | 0.57 | 0.96 | 1.40 | 0.01 | 0.01 | 0.01 | 0.01 |
| Foreign institutions | 18.13 | 20.19 | 21.57 | 22.69 | 24.44 | 25.72 | 26.46 | 23.86 | 22.11 | 21.69 | 0.21 | 0.21 | 0.20 | 0.21 |
| Government | — | — | — | — | — | — | — | — | — | 0.40 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 63.86 | 63.97 | 64.03 | 67.20 | 67.26 | 67.28 | 67.36 | 67.32 | 67.32 | 67.32 | 0.67 | 0.67 | 0.67 | 0.67 |
| Non-institutional | 38.23 | 36.62 | 35.07 | 38.08 | 35.88 | 34.76 | 34.11 | 33.98 | 33.84 | 33.67 | 0.33 | 0.32 | 0.31 | 0.30 |
| Shares outstanding | 12829889 | 12829889 | 12829889 | 12829889 | 12829889 | 12829889 | 12829889 | 12829889 | 12829889 | 12829889 | 12829889 | 12829889 | 12829889 | 12829889 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Neuland Laboratories Limited Employees Group Gratuity Scheme | Post Employment Benefit Trust | Any other transaction | 18,000,000,000,000.00 | 1 |
| Neuland Laboratories INC | Wholly owned Subsidiary | Any other transaction | 7,838,750,000,000.00 | 1 |
| Mr Davuluri Sucheth Rao | Vice-Chairman & CEO and KMP | Any other transaction, Remuneration | 2,963,233,100,000.00 | 3 |
| Mr Davuluri Saharsh Rao | Vice-Chairman & Managing Direc | Any other transaction, Remuneration | 2,963,233,100,000.00 | 3 |
| Dr Davuluri Rama Mohan Rao | Executive Chairman and KMP | Remuneration | 2,250,000,000,000.00 | 1 |
| Neuland Laboratories KK | Wholly owned Subsidiary | Any other transaction | 1,382,612,800,000.00 | 1 |
| Mr Abhijit Majumdar | Chief Financial Officer and KMP | Remuneration | 933,346,000,000.00 | 1 |
| Mrs Davuluri Vijaya Rao | Relative of Promoters | Any other transaction | 452,877,300,000.00 | 2 |
| Pallavi Bhakru | Non Executive Independent Director | Any other transaction | 276,000,000,000.00 | 1 |
| Mr Homi Rustam Khusrokhan | Non Executive Independent Director | Any other transaction | 276,000,000,000.00 | 1 |
| Dr Nirmala Murthy | Non Executive Independent Director | Any other transaction | 272,000,000,000.00 | 1 |
| Sugata Sircar | Non Executive Independent Director | Any other transaction | 270,000,000,000.00 | 1 |
| Prasad Raghava Menon | Non Executive Independent Director | Any other transaction | 268,000,000,000.00 | 1 |
| Dr Christopher M Cimarusti | Non-Executive Non-Independent Dire | Any other transaction | 260,000,000,000.00 | 1 |
| Mrs Bharati Rao | Non Executive Independent Director | Any other transaction | 252,000,000,000.00 | 1 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-10 | Q1FY27 | OFFICER, OFFICER AND MANAGING DIRECTOR | Read the call |
| 2026-05-16 | Q4FY26 | AND CHIEF EXECUTIVE OFFICER, OFFICER | Read the call |
| 2026-02-13 | Q3FY26 | MANAGING DIRECTOR, OFFICER | Read the call |
| 2025-11-12 | Q2FY26 | CORPORATE PLANNING & STRATEGY, MANAGING DIRECTOR | Read the call |
| 2025-08-04 | Q1FY26 | CHIEF EXECUTIVE OFFICER, CORPORATE PLANNING & STRATEGY, MANAGING DIRECTOR, OFFICER | Read the call |
| 2025-02-14 | Q3FY25 | CHIEF EXECUTIVE OFFICER, MANAGING DIRECTOR | Read the call |
| 2024-11-12 | Q2FY25 | EXECUTIVE OFFICER, MANAGING DIRECTOR | Read the call |
| 2024-08-06 | Q1FY25 | CORPORATE PLANNING & STRATEGY | Read the call |
| 2024-05-17 | Q4FY24 | 30% last year., LIMITED | Read the call |
| 2024-02-13 | Q3FY24 | LIMITED | Read the call |
| 2023-02-17 | Q3FY23 | ABHIJIT, NEULAND, NEULAND LABORATORIES LIMITED | Read the call |
| 2022-11-16 | Q2FY23 | LABORATORIES LIMITED, MANAGING DIRECTOR, NEULAND LABORATORIES, NEULAND LABORATORIES LIMITE | Read the call |
| 2022-08-08 | Q1FY23 | MANAGING DIRECTOR, NEULAND LABORATORIES, NEULAND LABORATORIES LIMITED | Read the call |
| 2022-05-31 | Q4FY22 | WHUU Ol'N>IUOt,.ITV IIOCOMU IUAll'fY | Read the call |
What they said about it, quarter by quarter
| Topic | Q2FY26 | Q3FY23 | Q3FY24 | Q3FY25 | Q3FY26 | Q4FY22 | Q4FY24 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | But irrespective of whether we decide to take up this path, I wanted to understand what is considered to be a sufficient CAPEX to attract large-scale … | We continue to invest in upgrading our facilities and have invested Rs.50.9 Crores in Capex during this period. | Broadly and it would likely be consistent with what we have said earlier normal CapEx would be around in the range of INR100 crores. | And another small part of that approved CAPEX is for enhancing the R&D scale peptide capabilities. | You talked about for the peptide molecule and why they are more keen and gives you the what about the renewed confidence you have in all the peptide c… | We continue to make investment in the WHUU Ol'N>ll.!Ot,.ITV IIOCOMU IUAUTY Neuland Laboratories Limited May 10, 2022 future and also for the CAPEX we … | Also, lastly, we are actively investing in long-term growth CapEx, which has been announced during the course of the year. | Or the dedicated capex we put some time back, and what are some of the messaging you are actually picking up from this transaction? |
| Capital allocation | — | — | — | — | — | — | So can you scratch out the capital allocation and dividend payout policy for the next four years. | — |
| Costs | So, we have been kind of putting inventory in, both in the form of raw material, starting materials, intermediates, right? | Our focus on execution excellence and cost has enabled us to minimize the cost impact from raw material increases facing our industry. | The product mix is excellent, and there has been no significant challenges in raw material prices, forex is kind of reasonably favourable. | — | So, I believe majority API should take approximately two weeks to manufacture only because even if 4-month manufacturing is there, this inventory, eve… | We continue to experience elevated costs across the value chain, for example, logistics, power and fuel, consumer goods and also we are witnessing som… | As always, we maintain that variables such as individual product performance, forex fluctuations, raw material cost volatility and other business vari… | — |
| Debt and cash | My second question is just on the cash flow. | 161 Crores in the 9M FY2023 and net debt position stands reduced to Rs. | — | At the moment, we don't have any definitive visibility on revenues or products or cash flow. | — | There is one question which is left out is on the net debt? | The second is when I'm actually coming to the working capital. | — |
| Demand | First is, despite a noticeable slowdown in the CDMO development pipeline, Neuland has added 25 new scientists. | I think if you go back to our con calls two years ago we had indicated that we have pipeline of several molecules, which are either completing phase t… | But where perhaps we're seeing some challenges in the early-stage pipeline, drugs which are kind of either in preclinical or maybe in the early clinic… | There is seems to be some sort of reversal in terms of the pipelines, so to speak. | So, when I look at the development pipeline, right, from preclinical to Phase III, that's kind of consistently drying up or that's the impression I'm … | The CMS business have grown by 5% for a full year on a Y-o-Y basis, reasons for this low growth, as industry demand seems to be very high? | Looking at the pipeline, we are excited on the long-term potential of the business. | I think the contribution has come from the products we've been looking at in our pipeline. |
| Guidance | The block is commissioned and we expect to start shipping product from it going forward. | As I had alluded earlier, we have a good visibility on the CMS business flow in terms of higher value projects over the short to medium-term and we ex… | Rahul, I think the way we had given our outlook, which is not really a guidance because it's not quantified. | So, some color around the entire peptide project and when can we expect like timelines and monetization of these assets? | I just want to understand Q4 and full year fiscal '26, what are we expecting again? | And if we talk about our CAPEX plans, it is on track and with greater commercialization of products which is happening and on the future commercial pr… | And we expect this momentum to sustain, bringing us heavy margins. | So should we rely on some of your past guidance on quantitative elements of the growth and margins? |
| Margin | So, I just want to know about the EBITDA margins, like because we have seen so much improvement in the EBITDA margins in this particular quarter. | Our EBITDA for the quarter stands at Rs. | And is my understanding right that the profit growth can actually be faster than the custom synthesis business where we have a very strong pipeline an… | Congratulations for turning around your business over the last 5 years from 12%-13% EBITDA basically operating margins to at least reaching 20 even in… | But on the gross margin side, even if you have 1 product, which is on the CDMO side, which might be on high gross margin side. | 39.3 crores with EBITDA margins of 15.3% points which was almost flat as compared to the previous year which was at 15.4% and it is increase of 100 ba… | So, we have seen a very favorable movement with the high-margin business increasing and the low-margin business coming down. | — |
| People | I think in terms of headcount, yes, there is a slight increase, again, because we are seeing an increased load in terms of projects. | Some of our late-stage products are being scaled up here hence we foresee unit 3 utilization continuing to move up. | My question is that what is the kind of utilization this plant 3 now has and I believe that you have taken a plant for subsequent factory expansion. | And do we look at this sort of the prime and the specialty piece more as a capacity utilization play to sort of combat the cyclicality of the CMS busi… | — | The utilization of Unit III continues to steadily increase as we keep scaling up these products. | So even as we are adding projects, we find that there is attrition in projects in Phase I, Phase II preclinical to Phase I therefore the number is at … | Would it be possible for the management to provide the capacity utilization across the 3 units at the moment? |
| Pricing | And if you could just share some scenario of what the pricing is right now, that would be helpful. | February 14, 2023 and both availability and the pricing of raw material and the pricing pressure of course on the product side. | And I thought that the CMS is a more profitable segment for us because it's a patented product and the customer wants more supply in security, trust i… | It's actually, I think maybe this question was asked in the past and it's a very difficult question to answer because there is a very wide range of wh… | — | — | Was there any comments on either pricing or volume trends for the quarter? | That's because how we fundamentally budget our numbers, whether it's exchange rates, raw material pricing, volumes, we tend to be slightly on the cons… |
| Revenue growth | And that is a product which is doing well and will continue to do well and probably it will drive the growth of the Prime business. | The revenue growth that will come I think will be evident in the coming couple of years and it is hard to paint a picture around it because saying a p… | And the revenue growth also has been impressive. | — | I understand why EBITDA margin could be lower because of the top line being lower and the fixed cost having to pay. | One of the reasons why the growth is only 5% is because we have also had offset due to the degrowth of one of our largest CMS molecules this year and … | — | — |
What they said they would do
Sentences in which management set an expectation. Each names the speaker and the page of the transcript it came from.
| Date | Quarter | Who | What they said |
|---|---|---|---|
| 2022-08-08 | Q1FY23 | NEULAND LABORATORIES LIMITED | Gross margin was 46.1% in Q1 of FY23 as compared to 41.5% in the last quarter and also 42.4% on Q1 of FY22. Also, we expect this shift portfolio to continue to drive higher gross margins. |
| 2022-11-16 | Q2FY23 | NEULAND LABORATORIES LIMITED | Gross margin was 56.2% in Q2 FY23 compared to 53.4% in Q1 FY23 and 49.2% in Q2 FY22. Further, we expect the shift in portfolio mix to continue to drive higher gross margins. |